Brief: Pliant Therapeutics Q4 Net Income USD -41.109 Million
27/02/2024 21:03
Feb 27 (Reuters) - Pliant Therapeutics Q4 operating expenses USD -47.037 million. * Q4 EPS USD 59904481 * Q4 operating income USD -47.037 million
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals